Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
June 2, 2022
Chinook Therapeutics (KDNY) public offering of 6,4 M shares priced at $14.00 raising $105 M
June 2, 2022
RegMed Investors (RMi) - Q1/22 Cell and Gene Therapy Earnings Scorecard Results
May 3, 2022
RegMed Investors: The week that will define the cell and gene therapy sector’s share pricing month
April 28, 2022
The Biostage (BSTG) Chronicles: Surgeon on trial in Sweden over experimental windpipe transplants
April 28, 2022
Alnylam Pharmaceuticals (ALNY) reports Q1/2022 earnings; net loss and net product revenue and collaboration decreases
March 22, 2022
Applied Genetic Technology (AGTC) prices 7.5 M share public offering
March 4, 2022
UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies
February 17, 2022
The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW)
January 11, 2022
The Biostage Chronicles: dispose and disregard, fit for the barrel
December 4, 2021
RegMed Investors (RMi): The week in review …
November 9, 2021
Chinook Therapeutics (KDNY) prices an upsized offering at $14.00 per share
October 30, 2021
The Biostage (BSTG) Chronicles: what’s there to invest in?
September 23, 2021
Q2/21 Earnings - (LPS - loss-per-share) Results
September 17, 2021
The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?
August 20, 2021
The Biostage (BSTG) Chronicles: Facts from filed 10-Q
August 13, 2021
The Biostage (BSTG) Chronicles - notice how the shares trade with and without being “pumped/promoted”?
July 22, 2021
The Biostage (BSTG) Chronicles – a number of questions have been asked and never answered
July 3, 2021
Intellia Therapeutics (NTLA) closes 4.758 M shares offering priced at $145.00 per share
June 23, 2021
The Biostage (BSTG) Chronicles: the annual meeting on Thursday 6/24/21, will there be any answers?
May 21, 2021
Biostage (BSTG) Chronicles: Another Q reporting MISS, why another missed date filing?
April 21, 2021
The Biostage (BSTG) Chronicles: post 10-K filing, too many questions remain unanswered
April 13, 2021
The Biostage (BSTG) Chronicles: Questions continue without any responses
April 7, 2021
The Biostage (BSTG) Chronicles: Questions continue without any answers to date
April 7, 2021
Homology Medicines (FIXX) prices $50 million offering at $7.90
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors